LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients

Long non-coding RNAs (lncRNAs) are functional RNAs longer than 200 nucleotides. Due to modern genomic techniques, the involvement of lncRNAs in tumorigenesis has been revealed; however, information concerning lncRNA interplay in multiple myeloma (MM) and plasma cell leukemia (PCL) is virtually absen...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Romana Bútová, Petra Vychytilová-Faltejsková, Jana Gregorová, Lenka Radová, Martina Almáši, Renata Bezděková, Lucie Brožová, Jiří Jarkovský, Zdeňka Knechtová, Martin Štork, Luděk Pour, Sabina Ševčíková
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	multiple myeloma plasma cell leukemia long non-coding RNA next-generation sequencing biomarkers disease progression Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/f43e6c946a264e1f92f59c50de106207
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f43e6c946a264e1f92f59c50de106207
record_format	dspace
spelling	oai:doaj.org-article:f43e6c946a264e1f92f59c50de1062072021-11-25T16:49:58ZLncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients10.3390/biomedicines91116372227-9059https://doaj.org/article/f43e6c946a264e1f92f59c50de1062072021-11-01T00:00:00Zhttps://www.mdpi.com/2227-9059/9/11/1637https://doaj.org/toc/2227-9059Long non-coding RNAs (lncRNAs) are functional RNAs longer than 200 nucleotides. Due to modern genomic techniques, the involvement of lncRNAs in tumorigenesis has been revealed; however, information concerning lncRNA interplay in multiple myeloma (MM) and plasma cell leukemia (PCL) is virtually absent. Herein, we aimed to identify the lncRNAs involved in MM to PCL progression. We investigated representative datasets of MM and PCL patients using next-generation sequencing. In total, 13 deregulated lncRNAs (<i>p</i> < 0.00025) were identified; four of them were chosen for further validation in an independent set of MM and PCL patients by RT-qPCR. The obtained results proved the significant downregulation of lymphocyte antigen antisense RNA 1 (LY86-AS1) and VIM antisense RNA 1 (VIM-AS1) in PCL compared to MM. Importantly, these two lncRNAs could be involved in the progression of MM into PCL; thus, they could serve as promising novel biomarkers of MM progression.Romana BútováPetra Vychytilová-FaltejskováJana GregorováLenka RadováMartina AlmášiRenata BezděkováLucie BrožováJiří JarkovskýZdeňka KnechtováMartin ŠtorkLuděk PourSabina ŠevčíkováMDPI AGarticlemultiple myelomaplasma cell leukemialong non-coding RNAnext-generation sequencingbiomarkersdisease progressionBiology (General)QH301-705.5ENBiomedicines, Vol 9, Iss 1637, p 1637 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	multiple myeloma plasma cell leukemia long non-coding RNA next-generation sequencing biomarkers disease progression Biology (General) QH301-705.5
spellingShingle	multiple myeloma plasma cell leukemia long non-coding RNA next-generation sequencing biomarkers disease progression Biology (General) QH301-705.5 Romana Bútová Petra Vychytilová-Faltejsková Jana Gregorová Lenka Radová Martina Almáši Renata Bezděková Lucie Brožová Jiří Jarkovský Zdeňka Knechtová Martin Štork Luděk Pour Sabina Ševčíková LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients
description	Long non-coding RNAs (lncRNAs) are functional RNAs longer than 200 nucleotides. Due to modern genomic techniques, the involvement of lncRNAs in tumorigenesis has been revealed; however, information concerning lncRNA interplay in multiple myeloma (MM) and plasma cell leukemia (PCL) is virtually absent. Herein, we aimed to identify the lncRNAs involved in MM to PCL progression. We investigated representative datasets of MM and PCL patients using next-generation sequencing. In total, 13 deregulated lncRNAs (<i>p</i> < 0.00025) were identified; four of them were chosen for further validation in an independent set of MM and PCL patients by RT-qPCR. The obtained results proved the significant downregulation of lymphocyte antigen antisense RNA 1 (LY86-AS1) and VIM antisense RNA 1 (VIM-AS1) in PCL compared to MM. Importantly, these two lncRNAs could be involved in the progression of MM into PCL; thus, they could serve as promising novel biomarkers of MM progression.
format	article
author	Romana Bútová Petra Vychytilová-Faltejsková Jana Gregorová Lenka Radová Martina Almáši Renata Bezděková Lucie Brožová Jiří Jarkovský Zdeňka Knechtová Martin Štork Luděk Pour Sabina Ševčíková
author_facet	Romana Bútová Petra Vychytilová-Faltejsková Jana Gregorová Lenka Radová Martina Almáši Renata Bezděková Lucie Brožová Jiří Jarkovský Zdeňka Knechtová Martin Štork Luděk Pour Sabina Ševčíková
author_sort	Romana Bútová
title	LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients
title_short	LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients
title_full	LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients
title_fullStr	LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients
title_full_unstemmed	LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients
title_sort	lncrnas ly86-as1 and vim-as1 distinguish plasma cell leukemia patients from multiple myeloma patients
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/f43e6c946a264e1f92f59c50de106207
work_keys_str_mv	AT romanabutova lncrnasly86as1andvimas1distinguishplasmacellleukemiapatientsfrommultiplemyelomapatients AT petravychytilovafaltejskova lncrnasly86as1andvimas1distinguishplasmacellleukemiapatientsfrommultiplemyelomapatients AT janagregorova lncrnasly86as1andvimas1distinguishplasmacellleukemiapatientsfrommultiplemyelomapatients AT lenkaradova lncrnasly86as1andvimas1distinguishplasmacellleukemiapatientsfrommultiplemyelomapatients AT martinaalmasi lncrnasly86as1andvimas1distinguishplasmacellleukemiapatientsfrommultiplemyelomapatients AT renatabezdekova lncrnasly86as1andvimas1distinguishplasmacellleukemiapatientsfrommultiplemyelomapatients AT luciebrozova lncrnasly86as1andvimas1distinguishplasmacellleukemiapatientsfrommultiplemyelomapatients AT jirijarkovsky lncrnasly86as1andvimas1distinguishplasmacellleukemiapatientsfrommultiplemyelomapatients AT zdenkaknechtova lncrnasly86as1andvimas1distinguishplasmacellleukemiapatientsfrommultiplemyelomapatients AT martinstork lncrnasly86as1andvimas1distinguishplasmacellleukemiapatientsfrommultiplemyelomapatients AT ludekpour lncrnasly86as1andvimas1distinguishplasmacellleukemiapatientsfrommultiplemyelomapatients AT sabinasevcikova lncrnasly86as1andvimas1distinguishplasmacellleukemiapatientsfrommultiplemyelomapatients
_version_	1718412933306777600

LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients

Ejemplares similares